Thursday, October 22, 2020

Tag: Pharmaceutical

Emerging Growth Pharmaceutical Companies

Cannabics Pharmaceuticals (CNBX) Prepares to Submit the FDA with a pre-IND...

Cannabics Pharmaceuticals (CNBX) Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33

Stocks that are most Vulnerable to a Biden Victory

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.

Why InflaRx (IFRX) Could Piggyback Off Regeneron’s Sudden Interest

After the initial deadly volley from the novel coronavirus, the broader healthcare industry’s attention shifted from developing treatments to researching and developing...

PAO Group, Inc. (PAOG) FDA Application Process For Respiratory Cannabis Drug...

PAO Group, Inc. (PAOG) FDA Application Process For Respiratory Cannabis Drug Treatment Update Scheduled This Friday

Throw $5,000.00 into any of these Coronavirus Vaccine Stocks

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.

MATEON’S (MATN) PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST...

MATEON’S (MATN) PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN ARGENTINA

Arizona State University/Halberd (HALB) Initiate Patent Application for Unique New Engineered...

Arizona State University/Halberd (HALB) Initiate Patent Application for Unique New Engineered Class of Covid-19 Antibody

Cheap Stocks to own before the Election

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.

AllStar Health Brands Inc., (ALST) Announces First Delivery of Equipment and...

AllStar Health Brands Inc., (ALST) Announces First Delivery of Equipment and Test Kits to Apogee Pharmaceuticals Inc. for Covid-19 Testing

Conversion Labs (CVLB) Expects Q3 2020 Record Revenue of $11.2 Million,...

Conversion Labs (CVLB) Expects Q3 2020 Record Revenue of $11.2 Million, up 254%; Subscription ARR Hits $19.3 million, up 458%